Edit

Exelixis

http://www.exelixis.com/

Last activity: 08.03.2026

Active

Categories: BioTechBusinessCauseCommerceDevelopmentDrugFutureMarketProductPublic

Following early work in model system genetics, Exelixis established a broad drug discovery and development platform that has served as the foundation for the company’s continued efforts to bring new cancer therapies to patients in need. Our discovery efforts have resulted in four commercially available products, and we have entered into partnerships with leading pharmaceutical companies to bring these important medicines to patients worldwide. Supported by revenues from our marketed products and collaborations, we are committed to prudently reinvesting in our business to maximize the potential of our pipeline. We are supplementing our existing therapeutic assets with targeted business development activities and internal drug discovery – all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer.

Please see our community guidelines: bit.ly/2XXw9w3.

To learn about us, visit www.exelixis.com/mission.

Likes

8.4K

Followers

5.78K

Website visits

24.9K /mo.

Mentions

Location: United States, California, Alameda

Employees: 501-1000

Phone: +1 650-837-7000

Founded date: 1994

Twitter

Facebook

Investors 3

Date	Name	Website
-	Domain Ass...	domainvc.c...
22.09.2022	Internatio...	ibtplc.com
-	Atlas Vent...	atlasventu...

Mentions in press and media 27

Date	Title	Description
08.03.2026	Выходец из МГУ привлек $293 млн на ИИ-платформу, которая находит кандидатов в лекарства за месяцы вместо лет	ИИ-платформа Pharma.AI компании Insilico Medicine нашла преклинического кандидата в лекарство за 8 месяцев — при отраслевой норме в 2,5–4 года. Компания, основанная выпускником МГУ Александром Жаворонковым, 30 декабря провела крупнейшее био...
27.01.2026	Insilico Medicine and Qilu Pharmaceutical Reach Near $120 Million Drug Development Collaboration to Accelerate Novel Cardiometabolic Therapies	CAMBRIDGE, Mass., Jan. 27, 2026 /PRNewswire/ -- Insilico Medicine, a clinical-stage biotechnology company powered by generative AI, and Qilu Pharmaceutical Group, a major comprehensive modern pharmaceutical enterprise in China, as well as i...
25.01.2026	AI-Powered Drug ISM8969 Gains FDA Nod for Parkinson's, Bolstering Neuroinflammation Fight	Insilico Medicine secured FDA Investigational New Drug (IND) approval for ISM8969. This AI-discovered, brain-penetrant NLRP3 inhibitor targets Parkinson's Disease. A Phase 1 clinical trial will soon begin in the U.S. This critical step acce...
23.01.2026	Insilico Medicine Receives IND Approval from FDA for ISM8969, an AI-empowered Potential Best-in-class NLRP3 Inhibitor	Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) paves the way for ISM8969 clinical study in the United States. The Phase I clinical trial aims to evaluate safety, tolerability, and pharmacokinetics p...
02.01.2026	AI Drug Discovery Pioneer Insilico Medicine Makes Landmark Hong Kong IPO	Insilico Medicine, an AI drug discovery leader, made its Hong Kong Stock Exchange debut. The company raised HKD 2.277 billion. This was 2025's largest biotech IPO in Hong Kong. The offering was heavily oversubscribed, attracting global capi...
31.12.2025	Qiming Venture Partners' Insilico Medicine Successfully Lists on Hong Kong Stock Exchange	SHANGHAI, Dec. 31, 2025 /PRNewswire/ -- Insilico Medicine (03696.HK), a global leader in AI-driven drug discovery and a portfolio company of Qiming Venture Partners, today successfully listed on the Hong Kong Stock Exchange (HKEX). The list...
30.12.2025	Insilico Medicine Lists on Hong Kong Stock Exchange, Showing AI Drug Discovery Momentum with 2025's Largest Hong Kong Biotech IPO	HONG KONG, Dec. 30, 2025 /PRNewswire/ -- Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial intelligence (AI), is successfully listed on the Hong Kong Stock Exchange today, b...
15.03.2025	Insilico Medicine: $110 Million (Series E) Raised For Advancing AI-Based Drug Discovery	Insilico Medicine (see Pulse 2.0 profile here), a clinical-stage generative AI-driven drug discovery company, announced that it has successfully secured a $110 million Series E financing led by a private equity fund of Value Partners Group ...
13.03.2025	Insilico Medicine Raises $110M in Series E Financing	Insilico Medicine, a Cambridge, MA-based clinical-stage generative artificial intelligence (AI)-driven drug discovery company, raised $110M in Series E funding. The round was led by Value Partners Group (HKG:0806) with participation from ne...
08.01.2025	Clarivate Identifies Eleven Potential Blockbuster and Transformative Drugs in Annual Drugs to Watch Report	Anticipated advancements in obesity, oncology, gene therapy and other areas poised to revolutionize patient care LONDON, Jan. 8, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today ...
18.07.2024	Frost & Sullivan Institute Celebrates Leaders in Sustainability with 2024 Enlightened Growth Leadership Awards	SANTA CLARA, Calif., July 18, 2024 /PRNewswire/ -- The Frost & Sullivan Institute is excited to announce the winners of the 2024 Enlightened Growth Leadership Best Practices Recognition from the Americas (LATAM and North Americas). This...
13.09.2023	Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor	— ISM3091 is a highly selective, orally bioavailable small molecule inhibitor of USP1 identified through Insilico Medicine's artificial intelligence (AI) platform, with potent activity in BRCA-mutated tumor models — — In May 2023, the U.S. ...
02.11.2022	Exelixis shells out $100M cash in a pair of deals, shooting for different takes on CD47, ADCs	Now that its cabozantinib franchise — including Cabometyx tablets and Cometriq capsules — has nestled its way into blockbuster status, Exelixis is replenishing the pipeline with some early-stage bets. The biotech revealed ...
14.10.2021	Exelixis and STORM enter into exclusive collaboration to discover and develop inhibitors of novel RNA modifying enzymes	Exelixis and STORM Therapeutics enter into exclusive collaboration and license agreement to discover and develop inhibitors of novel RNA modifying enzymes Exelixis, Inc. (Nasdaq: EXEL) and STORM Therapeutics (STORM) today announced that the...
30.06.2021	Will Exelixis Stock See Even Lower Levels After Negative Data From A Clinical Trial?	BRAZIL - 2020/11/04: In this photo illustration the Exelixis logo seen displayed on a smartphone. ... [+] (Photo Illustration by Rafael Henrique/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty Images
04.05.2021	Life Sciences portfolio company Gamamabs signs an agreement with Exelixis	To read the detailed press release, please click here
18.03.2021	Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate XL092 and Avelumab in Various Forms of Locally Advanced or Metastatic Ur...	ALAMEDA, Calif.--(BUSINESS WIRE)--Mar 18, 2021-- Exelixis, Inc. (Nasdaq:EXEL) today announced a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer for the ongoing phase 1b dose escalation study ...
25.02.2021	Exelixis Announces Breakthrough Therapy Designation Granted to Cabozantinib for the Treatment of Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer	ALAMEDA, Calif.--(BUSINESS WIRE)--Feb 25, 2021-- Exelixis, Inc. (NASDAQ: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to cabozantinib (CABOMETYX®) as a potential treatme...
08.09.2020	News briefing: Exelixis rolls the dice with 2 ADC deals tied to $35M cash upfronts; A rare antibiotic win for prominently-backed Spero	Peter Lamb Catalent’s Redwood Bioscience subsidiary is taking the lead role in developing ADCs for Exelixis $EXEL. In one of 2 deals announced this morning, Exelixis is turning to Catalent to do the discovery work on th...
04.09.2016	The biotech empires of Silicon Valley and Europe	Bérénice Magistretti Contributor Bérénice Magistretti is a Swiss freelance writer based in San Francisco. She focuses on startups in Saudi Arabia, Switzerland and emerging markets. More posts by this contributor Disrupting the world of scie...
17.04.2015	Stealth San Diego startup Metacrine raising $33M. Are we reassembling the Seragon team?	Evans, Metacrine’s founder, is a lauded gene expression researcher at the Salk Institute who has a number of successful (cancer and hormone-related) biotechs under his belt. Evans is known, according to his Salk profile, for his seminal hor...
15.10.2010	Exelixis Gets $60M from Bristol, Genentech Surpasses Original Herceptin, Synosia Pockets $30M, & More Bay Area Life Sciences News	Share Share on Facebook Share on Twitter LinkedIn Email Reprints News on cancer drugs, stem cells, and the rare item about promising drugs for Parkinson’s disease crossed our desk this week. —South San Francisco-based Exelixis (NASDAQ: EXEL...
-	Stealth San Diego startup Metacrine raising $33M. Are we reassembling the Seragon team?	An interesting new San Diego biotech – Metacrine – is in the works. CFO Trisha Millican said the company’s raised $6.85 million, and is aiming for $33 million – but otherwise is keeping silent on its dealings. So time for some extrapolation...
-	Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as a First-Line Treatment for Patients with Advanced Renal Cell Carcinoma...	ALAMEDA, Calif.--(BUSINESS WIRE)--Feb 26, 2021-- Exelixis, Inc. (NASDAQ: EXEL) today announced that its partner Ipsen received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of th...
-	Progress for patients in a pandemic: How one leading oncology company moved through 2020	By Michael M. Morrissey, Ph.D., president and chief executive officer, Exelixis, Inc. The Covid-19 pandemic radically altered 2020 for the biopharmaceutical industry and, of course, for society as a whole. Aspects of our industry’s business...
-	Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes.	California, USA and Cambridge, UK. 14 October 2021. STORM to deliver small molecule ADAR1 clinical candidate compounds discovered using its proprietary RNA modifying enzyme drug discovery platform. Exelixis, Inc. (Nasdaq: EXEL) and STORM ...
-	Stocks making the biggest moves midday: First Republic, UBS, Virgin Orbit, Dell and more	Check out the companies making the biggest moves midday: First Republic — Shares tanked 47.11% after Standard & Poor’s cut First Republic’s credit rating to B+ from BB+. S&P first lowered the bank’s rating to junk status just last w...

Exelixis

Investors 3

Mentions in press and media 27

Reviews 0